binders were prescribed. None of the enrolled patients was receiving statin or NaHCO~3~ per os. Forty-seven of our subjects (a ratio of 49%) were being treated by intravenous administration of vitamin D supplementation by using calcitriol or paricalcitol during dialysis session, depending mainly on serum calcium and phosphate levels. None of the enrolled patients had received intravenous administration of iron during the last 2 months before the start of the study. The total of enrolled subjects was treated with erythropoietin-α or-β agent in combination to orally receiving trivalent iron (ferric hydroxide polymaltose complex).

In our data, renal failure was caused by hypertensive nephrosclerosis at a ratio of 32.3%, chronic glomerulonephritis at a ratio of 28.1%, polycystic disease at a ratio 12.5%, diabetic nephropathy at a ratio equal to 11.5% and other causes at a ratio 15.6%.

2.2. Blood Collection {#sec2dot2-jcdd-05-00035}
---------------------

Blood was drawn at the same time point for each subject included in the study, just before the start of the mean weekly dialysis session in a 12 h fasting state from the vascular access. The received samples were centrifuged and the fresh serum was used for the biochemical measurements of the study. Serum was also conserved and processed for various assays.

2.3. Laboratory Measurements {#sec2dot3-jcdd-05-00035}
----------------------------

Albumin, glucose, calcium (Ca) corrected for the albumin levels, phosphate (P), cholesterol, triglycerides, low density lipoproteins (LDL) and high-density lipoproteins (HDL) were measured using spectrophotometric technique by Chemistry Analyzer (MINDRAY BS-200, Diamond Diagnostics, Holliston, MA, USA). The LDL/HDL ratio and the Ca × P products were calculated. Hematological analyzer (Sysmex, xt-4000i, Roche, Wiesbaden, Germany) was used for hemoglobin.

Oxidized LDL (ox-LDL) serum concentrations were measured using enzyme linked immunoabsorbed assay (ELISA), Immundiagnostik AG., Stubenwald-Allee (Bensheim, Germany), in acco